The demand for Remdesivir, an injectable drugs, has soared manifold amid skyrocketing coronavirus circumstances within the nation. Amid reviews of several states urgent the alarm button over the acute shortage of the key antiviral drug, manufacturers have now determined to scale back the price.
Union Minister for Chemicals and Fertilizers DV Sadananda Gowda on Friday stated that main manufacturers of Remdisivir have reduced the price significantly.
“On Govt’s intervention, major manufacturers of Remdesivir have voluntarily reduced its MRP ranging from Rs 5400 to less than Rs 3500 by 15.04.2021. This will support PM @narendramodi ‘s efforts to fight #COVID19,” Gowda stated in his tweet.
He added that the provision of the essential drugs has been ramped up in view of the largescale demand.
“Total 6.69 lacs vials of Remdesivir have been made available to different States/UTs of the country during the last 5 days. The supply has been ramped up in the most effective states. Government is taking every necessary step to accelerate the production facilities of Remdesivir, it’s capacity enhancement and availability,” the minister stated.
Meanwhile, the National Pharmaceutical Pricing Authority (NPPA) has requested manufacturers of Covid drug Remdesivir to implement the revised MRP by way of a voluntary discount of costs.
In a letter to Cadila Healthcare, Cipla Limited, Dr Reddy’s Labs, Hetero Drugs, Jubilant Pharma, Mylan Labs and Syngene International, the NPPA has sought compliance of revised MRP with respect to Remdesivir as per the DPCO, 2013.
“Based on the Form-V furnished regarding voluntary reduction in Maximum Retail Price (MRP) of Remdesivir, manufactures/marketers of Remdesivir are hereby directed to implement the revised MRP throughout the distribution chain w.e.f. 15.04.2021, irrespective of the batch numbers,” the NPPA stated.
Sun Pharma in a letter to retailers and stockists has requested them to implement the brand new MRP of Remwin which might be Rs 2,450, together with GST.
(With Inputs From IANS)